CanSino Biologics (6185) Announces Phase I Clinical Trial Launch and First Patient Enrollment for Inhaled TB Booster in Indonesia

Bulletin Express

Yesterday

CanSino Biologics Inc. (the “Company,” stock code: 6185) has officially initiated a Phase I clinical trial for its inhaled tuberculosis vaccine (Adenovirus Type 5 Vector), referred to as the inhaled TB Booster. The first trial patient for this inhaled TB Booster trial in Indonesia has been enrolled.

Current preventive measures for tuberculosis primarily rely on Bacillus Calmette-Guerin (BCG), which is widely used worldwide, especially for infants and children. However, BCG’s efficacy diminishes over time. To address this, the Company has developed a globally innovative TB Booster for BCG-vaccinated populations, with previous Phase Ia and Phase Ib trials conducted in Canada demonstrating its safety and efficacy. Building on its existing inhalation technology platform, the Company has upgraded the product by delivering it via aerosol inhalation, aiming to stimulate an immune response in the lungs more effectively.

The newly launched Phase I clinical trial in Indonesia involves participants aged 18 to 49, focusing on the safety and immunogenicity of a single-dose inhaled TB Booster. According to the announcement dated November 13, 2025, shareholders and potential investors are advised to exercise caution when dealing in the Company’s shares.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1126889477"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1126889477\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1126889477?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-13 17:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1126889477","market":"us","top_or_hot":-1,"title":"CanSino Biologics (6185) Announces Phase I Clinical Trial Launch and First Patient Enrollment for Inhaled TB Booster in Indonesia","media":"Bulletin Express","content":"<p>CanSino Biologics Inc. (the “Company,” stock code: 6185) has officially initiated a Phase I clinical trial for its inhaled tuberculosis vaccine (Adenovirus Type 5 Vector), referred to as the inhaled TB Booster. The first trial patient for this inhaled TB Booster trial in Indonesia has been enrolled.</p>\n<p>Current preventive measures for tuberculosis primarily rely on Bacillus Calmette-Guerin (BCG), which is widely used worldwide, especially for infants and children. However, BCG’s efficacy diminishes over time. To address this, the Company has developed a globally innovative TB Booster for BCG-vaccinated populations, with previous Phase Ia and Phase Ib trials conducted in Canada demonstrating its safety and efficacy. Building on its existing inhalation technology platform, the Company has upgraded the product by delivering it via aerosol inhalation, aiming to stimulate an immune response in the lungs more effectively.</p>\n<p>The newly launched Phase I clinical trial in Indonesia involves participants aged 18 to 49, focusing on the safety and immunogenicity of a single-dose inhaled TB Booster. According to the announcement dated November 13, 2025, shareholders and potential investors are advised to exercise caution when dealing in the Company’s shares.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CanSino Biologics (6185) Announces Phase I Clinical Trial Launch and First Patient Enrollment for Inhaled TB Booster in Indonesia</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCanSino Biologics (6185) Announces Phase I Clinical Trial Launch and First Patient Enrollment for Inhaled TB Booster in Indonesia\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2025-11-13 17:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CanSino Biologics Inc. (the “Company,” stock code: 6185) has officially initiated a Phase I clinical trial for its inhaled tuberculosis vaccine (Adenovirus Type 5 Vector), referred to as the inhaled TB Booster. The first trial patient for this inhaled TB Booster trial in Indonesia has been enrolled.</p>\n<p>Current preventive measures for tuberculosis primarily rely on Bacillus Calmette-Guerin (BCG), which is widely used worldwide, especially for infants and children. However, BCG’s efficacy diminishes over time. To address this, the Company has developed a globally innovative TB Booster for BCG-vaccinated populations, with previous Phase Ia and Phase Ib trials conducted in Canada demonstrating its safety and efficacy. Building on its existing inhalation technology platform, the Company has upgraded the product by delivering it via aerosol inhalation, aiming to stimulate an immune response in the lungs more effectively.</p>\n<p>The newly launched Phase I clinical trial in Indonesia involves participants aged 18 to 49, focusing on the safety and immunogenicity of a single-dose inhaled TB Booster. According to the announcement dated November 13, 2025, shareholders and potential investors are advised to exercise caution when dealing in the Company’s shares.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06185","symbol_name":"康希诺生物","start_time":0,"source_url":"","article_id":"1126889477","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1126889477","pubTimestamp":1763025763,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"CanSino Biologics Inc. (the “Company,” stock code: 6185) has officially initiated a Phase I clinical trial for its inhaled tuberculosis vaccine (Adenovirus Type 5 Vector), referred to as the inhaled...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06185":"康希诺生物"},"translate_title":"康希诺生物（6185）宣布在印尼开展吸入性结核病加强剂I期临床试验及首名患者入组","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06185":1},"content_text":"CanSino Biologics Inc. (the “Company,” stock code: 6185) has officially initiated a Phase I clinical trial for its inhaled tuberculosis vaccine (Adenovirus Type 5 Vector), referred to as the inhaled TB Booster. The first trial patient for this inhaled TB Booster trial in Indonesia has been enrolled.\nCurrent preventive measures for tuberculosis primarily rely on Bacillus Calmette-Guerin (BCG), which is widely used worldwide, especially for infants and children. However, BCG’s efficacy diminishes over time. To address this, the Company has developed a globally innovative TB Booster for BCG-vaccinated populations, with previous Phase Ia and Phase Ib trials conducted in Canada demonstrating its safety and efficacy. Building on its existing inhalation technology platform, the Company has upgraded the product by delivering it via aerosol inhalation, aiming to stimulate an immune response in the lungs more effectively.\nThe newly launched Phase I clinical trial in Indonesia involves participants aged 18 to 49, focusing on the safety and immunogenicity of a single-dose inhaled TB Booster. According to the announcement dated November 13, 2025, shareholders and potential investors are advised to exercise caution when dealing in the Company’s shares.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}